ANI PHARMACEUTICALS INC - 8-K Filing

ANI Pharmaceuticals reports Q3 2026 net revenues of $290.8 million and announces a ~$560 million offer to acquire Egetis Therapeutics. (Items: 2.02 and Item 7)

SEC EDGAR ·

Tickers: $ANIP

Read the full article at SEC EDGAR

More Regulatory news